Aisling Capital Management LP
Position in EPRX — Eupraxia Pharmaceuticals Inc.
CIK 1766721
NEW YORK, NY
Position in EPRX
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$2,353,000
New position
Shares Held
325,000
first reported quarter
Ownership
0.497%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
#21
of 54 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Aisling Capital Management LP holds $468,368,131 across 12 Biotechnology names. EPRX ranks #8 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
5,089,611 | $377,954,512 | |
| 2 | SNDX |
Syndax Pharmaceuticals Inc
|
1,316,806 | $30,760,588 | |
| 3 | GLUE |
Monte Rosa Therapeutics, Inc.
|
1,555,664 | $25,590,672 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
|
568,919 | $11,315,798 | |
| 5 | BBOT |
BridgeBio Oncology Therapeutics, Inc.
|
1,018,018 | $9,111,261 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
77,031 | $3,786,843 | |
| 7 | BMEA |
Biomea Fusion, Inc.
|
2,048,757 | $3,134,598 | |
| 8 | EPRX |
Eupraxia Pharmaceuticals Inc.
This page
|
325,000 | $2,353,000 |
All Filings in EPRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,353,000 | 325,000 | Shares | Sole | 2026-05-05 | |
| No filing history on record for this holder in this stock. | ||||||